Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
Open Access
- 7 October 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (4), 236-250
- https://doi.org/10.1016/j.clml.2021.09.021
Abstract
No abstract availableFunding Information
- Bristol-Myers Squibb
This publication has 101 references indexed in Scilit:
- Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristicsPatient Preference and Adherence, 2012
- Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemiaBlood, 2011
- Safety and efficacy of azacitidine in myelodysplastic syndromesDrug Design, Development and Therapy, 2010
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell LinesPLOS ONE, 2010
- Optimising the conditioning regimen for acute myeloid leukaemiaBest Practice & Research Clinical Haematology, 2009
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylationBlood, 2009
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood, 2009
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced CancersClinical Cancer Research, 2008
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Combining Anchor and Distribution-Based Methods to Derive Minimal Clinically Important Differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue ScalesJournal of Pain and Symptom Management, 2002